A Cheshire drug developer planned $425m merger with a US counterpart is under threat after a rival made an 'unsolicited' takeover bid.
Alderley Park's Redx Pharma and US-based Jounce Therapeutics originally announced the unanimously agreed deal last month.
However, it has now emerged that rival Concentra Biosciences, which is also based in the US, has made a bid to acquire Jounce Therapeutics.